510(k) device
Rejoyn
Otsuka America Pharmaceutical, Inc. · Computerized Behavioral Therapy Device For Depressive Disorders. (SAP, Class II) · First FDA decision Mar 30, 2024, newest Mar 30, 2024Depression
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
1
Naming "Rejoyn"
MAUDE reports
0
Brand "Rejoyn", since 2015
PubMed studies
8
Mentioning "Rejoyn"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Rejoyn
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Rejoyn510(k)
K231209 · Decided Mar 30, 2024 · 338 days after receipt
Device type: Computerized Behavioral Therapy Device For Depressive Disorders. (SAP) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Intensive Behavioral Therapy for ObesityNational analysisReview closedCAG-00423NUpdated Sep 18, 2026
- Intensive Behavioral Therapy for Cardiovascular DiseaseNational analysisReview closedCAG-00424NUpdated Sep 18, 2026
- Intensive Behavioral Therapy for ObesityNational determinationOn the books210.12Updated Dec 2, 2024
- Intensive Behavioral Therapy for Cardiovascular DiseaseNational determinationOn the books210.11Updated Dec 2, 2024
- Fluidized Therapy Dry Heat for Certain Musculoskeletal DisordersNational determinationOn the books150.8Updated Apr 17, 2020
- Transcranial Magnetic Stimulation (TMS) in the Treatment of Adults with Major Depressive DisorderLocal determinationIn effectL34522First Coast Service Options, Inc.Updated Oct 21, 2022
- Transcranial Magnetic Stimulation (TMS) in the Treatment of Adults with Major Depressive DisorderLocal determinationIn effectL34998Novitas Solutions, Inc.Updated Oct 21, 2022
Clinical trials
Device studies on ClinicalTrials.gov that name "Rejoyn", any status and sponsor, newest update first.
Yale UniversityAcademic, hospital or other
NCT07792252 · 50 participants (planned) · Start Sep 2026 · Primary completion Mar 2027
Device: Rejoyn · For: Major Depressive Disorder (MDD)
Sites: Greenwich, Connecticut; New Haven, Connecticut
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Rejoyn", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code SAP
1 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Rejoyn"[tiab]. The summary above synthesizes these.
- A digital therapeutic (CT-152) as adjunct to antidepressant medication: A phase 3 randomized controlled trial (the Mirai study).
Rothman B, Slomkowski M, Speier A, et al. · J Affect Disord · 2025Randomized Controlled Trial, Multicenter Study
- When Software Becomes Medicine: Ignoring It May Soon Be Malpractice.
Lakhan SE · Cureus · 2025Editorial
- Sentiment and Thematic Analysis of User Reviews for FDA-Cleared Prescription Digital Therapeutics: A Mixed-Methods Real-World Evidence Study.
Lakhan SE · Cureus · 2025
- A Dose of Smart Medicine to Make America Healthy Again: A $1 Trillion Win for Health, Innovation, and the Nation.
Lakhan SE · Cureus · 2025Editorial
- Enhancing mental wellness: A reflection on Rejoyn app's FDA approval for depression management.
Pokhrel P, Rath S, Aggarwal R, et al. · Asian J Psychiatr · 2024Letter
- Postmarket Safety Surveillance of FDA-Cleared Prescription Digital Therapeutics Using the Manufacturer and User Facility Device Experience (MAUDE) Database: A Pharmacovigilance Study.
Lakhan SE · Cureus · 2025
- Supporting the Primary Outcomes of the Mirai Trial for the Adjunctive Digital Therapeutic Rejoyn (CT-152) in the Treatment of Major Depressive Disorder: Meaningful Change Analysis in the Montgomery-Åsberg Depression Rating Scale.
Hudgens S, Purnajo I, Floden L, et al. · JMIR Form Res · 2026Clinical Trial, Phase III, Multicenter Study
- Coverage Policies, Benefit Routes, and Public Financial Terms for Prescription Digital Therapeutics in the United States: A Cross-Sectional Health Policy and Market Access Study.
Lakhan SE · Cureus · 2026
Other devices of this type
Also filed under product code SAP.
- Motivista (CT-155)Click Therapeutics, Inc. · 510(k) 2026
- MamaLift PlusCurio Digital Therapeutics, Inc. · 510(k) 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.